Masitinib treatment was linked to a nearly doubled five-year survival rate among people with amyotrophic lateral sclerosis (ALS),…
Articles by Michela Luciano, PhD
A team at Stanford University has received a $13 million grant to uncover previously unknown genetic causes of amyotrophic…
AC Immune’s experimental imaging agent ACI-19626 continues to show a good safety profile and has shown promise for detecting…
COYA 302, Coya Therapeutics’ investigational therapy for amyotrophic lateral sclerosis (ALS) — shown in an early clinical trial…
Shionogi has completed its acquisition of global rights to Radicava and Radicava ORS, two edaravone formulations approved to…
ACI-19626, an experimental imaging agent developed by AC Immune, may safely detect abnormal clumps of the protein TDP-43 in…
The ALS Society of Canada (ALS Canada) and Brain Canada have awarded a combined $515,000 to support four…
Coya Therapeutics has raised about $11.1 million in a private investment round to support commercial-readiness efforts for COYA 302,…
Patient enrollment has reached the halfway mark in an ongoing expanded access program (EAP) for MN‑166 (ibudilast), Medicinova’s oral…
Note: This story has been updated Jan. 16, 2026, to correct that once the therapy is delivered, the gene, not…